Taenia Infections Iowa State University Center for Food Security and Public Health
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
AAVP 1995 Annual Meeting Proceedings
Joint Meeting of The American Society of Parasitologists & The American Association of Veterinary Parasitologists July 6 july 1 0, 1995 Pittsburgh, Pennsylvania 2 ! j THE AMERICAN SOCIETY - OF PARASITOLOGISTS - & THE AMERICAN ASSOCIATION OF VETERINARY PARASITOLOGISTS ACKNOWLEDGE THEFOLLO~GCO~ANlliS FOR THEIR FINANCIAL SUPPORT: CORPORATE EVENT SPONSOR: PFIZER ANIMAL HEALTH CORPORATE SPONSORS: BOEHRINGER INGELHEIM ANIMAL HEALTH, INC. MALUNCKRODT VETERINARY, INC. THE UPJOHN CO. MEETING SPONSORS: AMERICAN CYANAMID CO. CIBA ANIMAL HEALTH ELl LILLY & CO. FERMENT A ANIMAL HEALTH HILL'S PET NUTRITION, INC. HOECHST-ROUSSEL AGRI-VET CO. IDEXX LABORATORIES, INC. MIDWEST VETERINARY SERVICES, INC. PARA VAX, INC. PROFESSIONAL LABORATORIES & RESEARCH SERVICES RHONE MERIEUX, INC. SCHERING-PLOUGH ANIMAL HEALTH SOLVAY ANIMAL HEALTH, INC. SUMITOMO CHEMICAL, LTO. SYNBIOTICS CORP. TRS LABS, INC. - - I I '1---.. --J 3 Announcing a Joint Meeting of THE AMERICAN SOCIETY THE AMERICAN ASSOCIATION Of OF PARASITOLOGISTS VETERINARY PARASITOLOGISTS (70th Meeting) (40th Meeting) Pittsburgh, Pennsylvania july 6-1 0, 1995 INFORMATION & REGISTRATION Hyatt Regency Hotel, 112 Washington Place THURSDAY Regency foyer, 2nd Floor t July 6th Registration Begins, Noon-5:00 p.m. FRIDAY Regency foyer, 2nd Floor t July 7th 8:00 a.m.-5:00 p.m. SATURDAY Regency foyer, 2nd Floor july 8th 8:00 a.m.-5:00p.m. SUNDAY Regency foyer, 2nd Floor july 9th 8:00 a.m.-Noon t Items for the Auction may be delivered to this location before 3:00p.m. on Friday, july 7th. 4 WELCOME RECEPTION Thursday, july 6th 7:00-1 0:00 p.m. Grand Ballroom SOCIAl, MATCH THE FACES & AUCTION Friday, July 7th Preview: 6:30-7:30 p.m. -
WSAVA List of Essential Medicines for Cats and Dogs
The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs ..................................................................................................................... -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Sheet1 Page 1 a Abamectin Acetazolamide Sodium Adenosine-5-Monophosphate Aklomide Albendazole Alfaxalone Aloe Vera Alphadolone A
Sheet1 A Abamectin Acetazolamide sodium Adenosine-5-monophosphate Aklomide Albendazole Alfaxalone Aloe vera Alphadolone Acetate Alpha-galactosidase Altrenogest Amikacin and its salts Aminopentamide Aminopyridine Amitraz Amoxicillin Amphomycin Amphotericin B Ampicillin Amprolium Anethole Apramycin Asiaticoside Atipamezole Avoparcin Azaperone B Bambermycin Bemegride Benazepril Benzathine cloxacillin Benzoyl Peroxide Benzydamine Bephenium Bephenium Hydroxynaphthoate Betamethasone Boldenone undecylenate Boswellin Bromelain Bromhexine 2-Bromo-2-nitropan-1, 3 diol Bunamidine Buquinolate Butamisole Butonate Butorphanol Page 1 Sheet1 C Calcium glucoheptonate (calcium glucoheptogluconate) Calcium levulinate Cambendazole Caprylic/Capric Acid Monoesters Carbadox Carbomycin Carfentanil Carnidazole Carnitine Carprofen Cefadroxil Ceftiofur sodium Centella asiatica Cephaloridine Cephapirin Chlorine dioxide Chlormadinone acetate Chlorophene Chlorothiazide Chlorpromazine HCl Choline Salicylate Chondroitin sulfate Clazuril Clenbuterol Clindamycin Clomipramine Clopidol Cloprostenol Clotrimazole Cloxacillin Colistin sulfate Copper calcium edetate Copper glycinate Coumaphos Cromolyn sodium Crystalline Hydroxycobalamin Cyclizine Cyclosporin A Cyprenorphine HCl Cythioate D Decoquinate Demeclocycline (Demethylchlortetracycline) Page 2 Sheet1 Deslorelin Desoxycorticosterone Pivalate Detomidine Diaveridine Dichlorvos Diclazuril Dicloxacillin Didecyl dimethyl ammonium chloride Diethanolamine Diethylcarbamazine Dihydrochlorothiazide Diidohydroxyquin Dimethylglycine -
Simparica Trio
Simparica Trio and Simparica Satisfaction Guarantee If you or your clients feel that Simparica TrioTM (sarolaner, moxidectin, and pyrantel chewable tablets) or Simparica® (sarolaner) Chewables aren’t providing sufficient protection, please call our medical support team to discuss our Satisfaction Guarantee. We will work with you to ensure that you and your clients are satisfied with the performance of Simparica Trio or Simparica or we will refund the cost of your purchase.* The Simparica Trio and Simparica Satisfaction Guarantee is available to any individual who has purchased Simparica Trio or Simparica from a veterinarian or via a veterinarian’s prescription from a Zoetis approved online distributor.** HEARTWORM DISEASE GUIDELINES (SIMPARICA TRIO ONLY): If any dog determined by a licensed veterinarian to be free of heartworm infection at the onset of treatment with Simparica Trio develops heartworm disease, we will provide reimbursement (up to $1,000 and provide Diroban® (melarsomine dihydrochloride) or provide reasonable acquisition costs of melarsomine dihydrochloride) associated with the diagnosis and treatment of heartworm disease and provide a year’s supply of Simparica Trio or ProHeart® 6 (moxidectin) or ProHeart® 12 (moxidectin). Canine Heartworm Reimbursement Requirements: • Simparica Trio was used, at all times, according to its label directions. • Confirmation of heartworm-positive status by two separate blood samples using at least two different brands of antigen tests are required to document heartworm positive status. – The use of an antigen test will be the standard for determining heartworm status. – Knott’s or any filter test for the detection of microfilariae is nots ufficient evidence for pretreatment heartworm negative status. -
Faculdade De Medicina Veterinária
UNIVERSIDADE DE LISBOA Faculdade de Medicina Veterinária THE FIRST EPIDEMIOLOGICAL STUDY ON THE PREVALENCE OF CARDIOPULMONARY AND GASTROINTESTINAL PARASITES IN CATS AND DOGS FROM THE ALGARVE REGION OF PORTUGAL USING THE FLOTAC TECHNIQUE SINCLAIR PATRICK OWEN CONSTITUIÇÃO DO JURÍ ORIENTADOR Doutor José Augusto Farraia e Silva Doutor Luís Manuel Madeira de Carvalho Meireles Doutor Luís Manuel Madeira de Carvalho CO-ORIENTADOR Mestre Telmo Renato Landeiro Raposo Dr. Dário Jorge Costa Santinha Pina Nunes 2017 LISBOA UNIVERSIDADE DE LISBOA Faculdade de Medicina Veterinária THE FIRST EPIDEMIOLOGICAL STUDY ON THE PREVALENCE OF CARDIOPULMONARY AND GASTROINTESTINAL PARASITES IN CATS AND DOGS FROM THE ALGARVE REGION OF PORTUGAL USING THE FLOTAC TECHNIQUE SINCLAIR PATRICK OWEN DISSERTAÇÃO DE MESTRADO INTEGRADO EM MEDICINA VETERINÁRIA CONSTITUIÇÃO DO JURÍ ORIENTADOR Doutor José Augusto Farraia e Silva Doutor Luís Manuel Madeira de Carvalho Meireles CO-ORIENTADOR Doutor Luís Manuel Madeira de Carvalho Dr. Dário Jorge Costa Santinha Mestre Telmo Renato Landeiro Raposo Pina Nunes 2017 LISBOA ACKNOWLEDGEMENTS This dissertation and the research project that underpins it would not have been possible without the support, advice and encouragement of many people to whom I am extremely grateful. First and foremost, a big thank you to my supervisor Professor Doctor Luis Manuel Madeira de Carvalho, a true gentleman, for his unwavering support and for sharing his extensive knowledge with me. Without his excellent scientific guidance and British humour this journey wouldn’t have been the same. I would like to thank my co-supervisor Dr. Dário Jorge Costa Santinha, for welcoming me into his Hospital and for everything he taught me. -
The Influence of Human Settlements on Gastrointestinal Helminths of Wild Monkey Populations in Their Natural Habitat
The influence of human settlements on gastrointestinal helminths of wild monkey populations in their natural habitat Zur Erlangung des akademischen Grades eines DOKTORS DER NATURWISSENSCHAFTEN (Dr. rer. nat.) Fakultät für Chemie und Biowissenschaften Karlsruher Institut für Technologie (KIT) – Universitätsbereich genehmigte DISSERTATION von Dipl. Biol. Alexandra Mücke geboren in Germersheim Dekan: Prof. Dr. Martin Bastmeyer Referent: Prof. Dr. Horst F. Taraschewski 1. Korreferent: Prof. Dr. Eckhard W. Heymann 2. Korreferent: Prof. Dr. Doris Wedlich Tag der mündlichen Prüfung: 16.12.2011 To Maya Index of Contents I Index of Contents Index of Tables ..............................................................................................III Index of Figures............................................................................................. IV Abstract .......................................................................................................... VI Zusammenfassung........................................................................................VII Introduction ......................................................................................................1 1.1 Why study primate parasites?...................................................................................2 1.2 Objectives of the study and thesis outline ................................................................4 Literature Review.............................................................................................7 2.1 Parasites -
Severe Coenurosis Caused by Larvae of Taenia Serialis in an Olive Baboon (Papio Anubis) in Benin T
IJP: Parasites and Wildlife 9 (2019) 134–138 Contents lists available at ScienceDirect IJP: Parasites and Wildlife journal homepage: www.elsevier.com/locate/ijppaw Severe coenurosis caused by larvae of Taenia serialis in an olive baboon (Papio anubis) in Benin T ∗ E. Chanoveb, , A.M. Ionicăa, D. Hochmanc, F. Berchtolda, C.M. Ghermana, A.D. Mihalcaa a Department of Parasitology and Parasitic Diseases, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Calea Mănăștur 3-5, Cluj-Napoca, 400372, Romania b Department of Infectious Diseases, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Calea Mănăștur 3-5, Cluj-Napoca, 400372, Romania c Veterinary Clinic “du clos”, 67 rue de la chapelle, Saint-Cergues, 74140, France ARTICLE INFO ABSTRACT Keywords: In March 2017, a captive male juvenile (ca. 6 months old) olive baboon (Papio anubis) was brought to a primate Olive baboon rescue center in Benin with multiple subcutaneous swellings of unknown aetiology. At the general inspection of Intermediate host the body, around 15 partially mobile masses of variable sizes were found in different locations across the body. Taenia serialis Following two surgical procedures, several cyst-like structures were removed and placed either in 10% formalin Coenurus or in absolute ethanol. The cysts had a typical coenurus-like morphology. Genomic DNA was extracted from one cyst using a commercially available kit. The molecular characterization was performed by PCR amplification and sequencing of a region of the nuclear ITS-2 rDNA and a fragment of the mitochondrial 12S rDNA gene, revealing its identity as T. serialis, with 88%–98% similarity to T. -
Addendum A: Antiparasitic Drugs Used for Animals
Addendum A: Antiparasitic Drugs Used for Animals Each product can only be used according to dosages and descriptions given on the leaflet within each package. Table A.1 Selection of drugs against protozoan diseases of dogs and cats (these compounds are not approved in all countries but are often available by import) Dosage (mg/kg Parasites Active compound body weight) Application Isospora species Toltrazuril D: 10.00 1Â per day for 4–5 d; p.o. Toxoplasma gondii Clindamycin D: 12.5 Every 12 h for 2–4 (acute infection) C: 12.5–25 weeks; o. Every 12 h for 2–4 weeks; o. Neospora Clindamycin D: 12.5 2Â per d for 4–8 sp. (systemic + Sulfadiazine/ weeks; o. infection) Trimethoprim Giardia species Fenbendazol D/C: 50.0 1Â per day for 3–5 days; o. Babesia species Imidocarb D: 3–6 Possibly repeat after 12–24 h; s.c. Leishmania species Allopurinol D: 20.0 1Â per day for months up to years; o. Hepatozoon species Imidocarb (I) D: 5.0 (I) + 5.0 (I) 2Â in intervals of + Doxycycline (D) (D) 2 weeks; s.c. plus (D) 2Â per day on 7 days; o. C cat, D dog, d day, kg kilogram, mg milligram, o. orally, s.c. subcutaneously Table A.2 Selection of drugs against nematodes of dogs and cats (unfortunately not effective against a broad spectrum of parasites) Active compounds Trade names Dosage (mg/kg body weight) Application ® Fenbendazole Panacur D: 50.0 for 3 d o. C: 50.0 for 3 d Flubendazole Flubenol® D: 22.0 for 3 d o. -
Selection of New Chemicals to Be Used in Conditioned Aversion for Non-Lethal Predation Control 2
1 Selection of new chemicals to be used in conditioned aversion for non-lethal predation control 2 3 Jorge Tobajasa,*, Pilar Gómez-Ramíreza,b,c, Pedro María-Mojicab, Isabel Navasb,c, 4 Antonio Juan García-Fernándezb,c, Pablo Ferrerasa, Rafael Mateoa 5 6 aInstituto de Investigación en Recursos Cinegéticos (IREC), CSIC-UCLM-JCCM, Ronda de 7 Toledo No. 12, 13071, Ciudad Real, Spain. 8 bToxicology Area, Department of Health Sciences, Faculty of Veterinary, University of 9 Murcia, Campus de Espinardo, 30100 Murcia, Spain. 10 cToxicology and Risk Assessment Group, Biomedical Research Institute of Murcia (IMIB- 11 Arrixaca), University of Murcia, Campus de Espinardo, 30100 Murcia, Spain. 12 13 *Corresponding author 14 E-mail address: [email protected] (J. Tobajas) 15 1 16 Abstract 17 The use of conditioned food aversion (CFA) can reduce the predation conflict and 18 therefore the incidence of illegal poisoning, which is one of the most important 19 conservation threats for predators and scavengers around the world. CFA is a robust 20 learning paradigm that occurs when animals associate a food with a discomfort 21 induced by a chemical, thereby avoiding that food in subsequent encounters. We 22 reviewed the potential of 167 chemical compounds to be used in CFA, considering 23 effects, margin of safety, accessibility, and detectability. After the review, 15 24 compounds fulfilled the required characteristics, but only five were finally selected to 25 be tested in CFA assays with dogs. Of the tested compounds, thiabendazole, thiram 26 and levamisole caused target food rejection by dogs and reduced the time spent eating 27 during post-conditioning. -
EPSIPRANTEL Veterinary—Oral-Local
EPSIPRANTEL Veterinary—Oral-Local A commonly used brand name for a veterinary-labeled Chemical name: (±)-2-(Cyclohexylcarbonyl)- product is Cestex. 2,3,6,7,8,12b-hexahydropyrazino[2, 1- {R-4} a][2]benzazepin-4(1H)-one. {R-4} Note: For a listing of dosage forms and brand names by Molecular formula: C20H26N202. country availability, see the Dosage Forms Molecular weight: 326.43.{R-1; 4} {R-1} section(s). Description: A stable, white solid. {R-1} Solubility: Sparingly soluble in water. Category: Anthelmintic. Pharmacology/Pharmacokinetics Indications Mechanism of action/Effect: The mechanism of Note: The text between ELUS and EL describes uses that action of epsiprantel appears to be similar to that of are not included in U.S. product labeling. Text praziquantel, a drug that disrupts the regulation of between ELCAN and EL describes uses that are not calcium and other cations. Tetanic muscle included in Canadian product labeling. contraction and paralysis occurs in the parasite, and {R-8; 10} The ELUS or ELCAN designation may signify a lack the tegument becomes vacuolized. of product availability in the country indicated. Absorption: Minimal absorption occurs in cats and See the Dosage Forms section of this monograph {R-1; 5} to confirm availability. dogs after oral administration. Biotransformation: There is no evidence that Cats and dogs {R-8} Accepted epsiprantel is metabolized. Cestode, gastrointestinal, infection (treatment)— Epsiprantel tablets are indicated in the treatment of Concentrations: Peak plasma concentration— tapeworms, Dipylidium caninum in cats and dogs, Cats: In 83% of cats in one study, the plasma Taenia taeniaeformis in cats, and Taenia pisiformis concentration of epsiprantel was below the level in dogs.{R-1} of detection in all samples taken after an oral dose of 5.5 mg per kg of body weight (mg/kg).{R- 8} Potentially effective When plasma epsiprantel could be measured, the peak concentration was 0.21 mcg/mL at 30 Cestode, gastrointestinal, infection (treatment)—Cats {R-8} ELUS,CAN minutes after administration of the dose. -
Canine and Feline Parasite Control at Home and Abroad
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Canine and feline parasite control at home and abroad Author : Ian Wright Categories : Companion animal, Vets Date : June 13, 2016 ABSTRACT The European Scientific Counsel Companion Animal Parasites (ESCCAP) UK and Ireland is a national association of ESCCAP Europe, bringing together some of the UK and Ireland’s leading experts in the field of veterinary parasitology. ESCCAP UK and Ireland works with pet owners and professionals to raise awareness of the threat from parasites and provide relevant information and advice. Part of this service is to answer questions from the public and veterinary professionals asked via www.esccapuk.org.uk This article addresses the most common questions asked that are of particular relevance to veterinary professionals. The European Scientific Counsel Companion Animal Parasites (ESCCAP) UK and Ireland is a national association of ESCCAP Europe, bringing together some of the UK and Ireland’s leading experts in the field of veterinary parasitology. 1 / 11 Figure 1. Flea bite reaction. ESCCAP UK and Ireland is independent, working with pet owners and professionals to raise awareness of the threat from parasites and provide relevant information and advice. Part of this service is to answer questions from the public and veterinary professionals, asked via www.esccapuk.org.uk Some questions are specific to individual circumstances, such as trematodes present in Asia and parasites present in the Middle East. Others, however, are asked frequently and of more general relevance to UK veterinary professionals. Some examples are discussed in this article and fall into four broad categories: ectoparasite control in households macrocyclic lactone use European pet travel advice Babesia canis prevention in dogs Ectoparasite control in households Questions are often asked about parasites found in the home – either when life stages are discovered in the house or when ectoparasites are found on pets.